Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL235202 | 0.96 | — | — | |
| SCHEMBL674050 | 0.91 | CXCR4 (0.53) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT | |
| SCHEMBL1782168 | 0.90 | CXCR4 (0.41) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT | |
| SCHEMBL1779850 | 0.90 | CXCR4 (0.50) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT | |
| SCHEMBL10036 | 0.90 | — | — | |
| SCHEMBL567977 | 0.87 | ALDH1A1 (0.56) | CXCR4SMN1; SMN2ALDH1A1 | |
| SCHEMBL674177 | 0.83 | ALDH1A1 (0.60) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT | |
| SCHEMBL175198 | 0.80 | — | — | |
| SCHEMBL566326 | 0.78 | ALDH1A1 (0.53) | CXCR4SMN1; SMN2ALDH1A1 | |
| SCHEMBL18687 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111533744-A | Non-viral vector, preparation method and application thereof | 德州学院 | 2020-08-14 | — | — | CN | claimed |
| EP-2991980-B1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-01-02 | — | — | EP | claimed |
| US-8722956-B2 | Kit for decomposing organophosphorus compounds | QUEEN'S UNIVERSITY AT KINGSTON (US) | 2014-05-13 | — | — | US | claimed |
| EP-1613402-B1 | METHOD OF DECOMPOSING ORGANOPHOSPHORUS COMPOUNDS | UNIV KINGSTON (CA) | 2013-01-16 | — | — | EP | claimed |
| US-20110253580-A1 | Method of Decomposing Organophosphorus Compounds | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2011-10-20 | — | — | US | claimed |
| US-7875739-B2 | Detoxification of hazardous materials; rapid lanthanum ion catalyzed alcoholysis | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2011-01-25 | — | — | US | claimed |
| US-20070299275-A1 | Method of decomposing organophosphorus compounds | BROWN R S | 2007-12-27 | — | — | US | claimed |
| US-7214836-B2 | Method of decomposing organophosphorus compounds | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2007-05-08 | — | — | US | claimed |
| US-20040230082-A1 | Method of decomposing organophosphorus compounds | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2004-11-18 | — | — | US | claimed |
| EP-3367820-B1 | PREPARATION OF MODIFIED CELLULOSE AND ITS DERIVATIVES | INNOTECH MAT LLC (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-110582485-B | Pyrazole derivatives as bromodomain inhibitors | 葛兰素史克知识产权第二有限公司 | 2023-10-13 | — | — | CN | disclosed |
| EP-3589618-B1 | PYRAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2022-12-28 | — | — | EP | disclosed |
| CN-109153646-B | Pyridine dicarboxamide derivatives as bromodomain inhibitors | 葛兰素史克知识产权第二有限公司 | 2022-08-02 | — | — | CN | disclosed |
| EP-3692026-B1 | BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS. | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2022-07-06 | — | — | EP | disclosed |
| EP-0937042-A1 | HETEROARYL SUCCINAMIDES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1999-08-25 | — | — | EP | disclosed |
| US-5925759-A | PRODUCING NELFINAVIR MESYLATE FROM TARTARIC ACID | AGOURON PHARMACEUTICALS, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| EP-0874830-A1 | METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES, AND METHODS AND INTERMEDIATES USEFUL FOR THEIR PREPARATION | AGOURON PHARMACEUTICALS, INC. (US) | 1998-11-04 | — | — | EP | disclosed |
| WO-1998017643-A1 | HETEROARYL SUCCINAMIDES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1998-04-30 | — | — | WO | disclosed |
| US-5705647-A | BENZOIC ACID OXAZOLE DERIVATIVES FOR TREATMENT OF AIDS | AGOURON PHARMACEUTICALS, INC. (US) | 1998-01-06 | — | — | US | disclosed |
| WO-1997020824-A1 | METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES, AND METHODS AND INTERMEDIATES USEFUL FOR THEIR PREPARATION | AGOURON PHARMACEUTICALS, INC. (US) | 1997-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299275-A1 | Method of decomposing organophosphorus compounds | ACHE, L3MBTL3, L3MBTL4 | CXCR4 3927/4885SMN1; SMN2 138/4885ALDH1A1 618/4885 |
| US-20040230082-A1 | Method of decomposing organophosphorus compounds | ACHE, L3MBTL3, L3MBTL4 | CXCR4 3927/4885SMN1; SMN2 138/4885ALDH1A1 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.